Verrica Pharmaceuticals Inc(VRCA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.67 | Insider Own | 49% | Shs Outstand | 17.2M | Perf Week | - |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | 34.55% | Insider Trans | 0.5% | Shs Float | 8.8M | Perf Month | -24.57% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.5 | Inst Own | 27.14% | Short Float | 2.2% | Perf Quarter | -33.01% |
| Income | -0.03B | P/S | 1.97 | EPS this Y | -21.69% | Inst Trans | -0.75% | Short Ratio | 2.74 | Perf Half Y | -46.86% |
| Sales | 0.03B | P/B | 13.84 | EPS next 5Y | 8.78% | ROA | -83.02% | Short Interest | 0.19M | Perf YTD | -58.24% |
| Book/sh | 0.25 | P/C | 5.32 | EPS past 3/5Y | 38.35% 37.12% | ROE | -240.35% | 52W High | -64.67% ($9.82) | Perf Year | -7.71% |
| Cash/sh | 0.65 | P/FCF | - | Sales past 3/5Y | 57.93% - | ROIC | -604.2% | 52W Low | 5.79% ($3.28) | Perf 3Y | -89.7% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 79.84% | Gross Margin | 85.89% | Volatility(W/M) | 9.92% 9.16% | Perf 5Y | -97.3% |
| Dividend TTM | - | EV/Sales | 1.66 | Sales Y/Y TTM | 106.21% | Oper. Margin | -87.18% | ATR (14) | 0.34 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.21 | EPS Q/Q | -2971.63% | Profit Margin | -102.84% | RSI (14) | 36.29 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.33 | Sales Q/Q | -53.85% | SMA20 | -11.28% ($3.91) | Beta | 1.66 | Target Price | $13.83 |
| Payout | - | Debt/Eq | 0.42 | Earnings | 2026/8/6 | SMA50 | -22.75% ($4.49) | Rel Volume | 0.4 | Prev Close | $3.42 |
| Employees | 76 | LT Debt/Eq | 0.2 | EPS/Sales Surpr. | -60% 2.24% | SMA200 | -38.86% ($5.68) | Avg Volume(3M) | 0.07M | Price | $3.47 |
| IPO | 2018/6/15 | Option/Short | Yes/Yes | Trades | 218 | Volume | 27,994 | Change | 1.46% |
🧴 Verrica Pharmaceuticals is a U.S.-based biopharmaceutical company focused on treating skin diseases. Its core business is the development and commercialization of topical therapies for skin lesions, including treatments for molluscum contagiosum (water warts), and the company is expanding its presence in the dermatology market by targeting unmet needs where standard treatment options have been limited.
Over the past 1 year, on the lower side
65% below its 1-year high.
Traded less than usual. That is 40% of its average volume.
VRCA has a sound balance sheet but weak earning power
Of every $100 in sales, $87.18 is lost.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -21.7% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $197. Peers typically go for $1,034.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.3%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 27.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #398 of 594 in the industry
Based on market cap of $60M.
RNTX#396 Rein Therapeutics Inc $61M PER - 
GOSS#397 Gossamer Bio Inc $60M PER - VRCA#398 Verrica Pharmaceuticals Inc $60M PER - 
ONCY#399 Oncolytics Biotech Inc $59M PER - 
OSTX#400 OS Therapies Inc $58M PER - 
FAQ
What kind of company is VRCA?
VRCA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VRCA?
The market cap of VRCA is approximately $60M, ranking 4,748 within its sector.
What is the 52-week high and low for VRCA?
VRCA has recorded a 52-week high of $9.82 and a low of $3.28.
